Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab – case report

1 NHS England. 2013/14 NHS standard contract for haemophilia (all ages). Section B part 1 – Service specifications. B05/S/a. NHS Commissioning Service, 2013. Available from https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf (accessed 30 September 2021). NHS England 2013/14 NHS standard contract for haemophilia (all ages). Section B part 1 – Service specifications B05/S/a. NHS Commissioning Service, 2013 Available from https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf (accessed 30 September 2021). Search in Google Scholar

2 NICE Commissioning Support Programme for NHS England Specialised Services. Clinical Commissioning Policy: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages). 170067/P. NHS England, July 2018. Available from https://www.england.nhs.uk/publication/clinical-commissioning-policy-emicizumab-as-prophylaxis-in-people-with-congenital-haemophilia-a-with-factor-viii-inhibitors-all-ages/ (accessed 30 September 2021). NICE Commissioning Support Programme for NHS England Specialised Services Clinical Commissioning Policy: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages) 170067/P. NHS England, July 2018 Available from https://www.england.nhs.uk/publication/clinical-commissioning-policy-emicizumab-as-prophylaxis-in-people-with-congenital-haemophilia-a-with-factor-viii-inhibitors-all-ages/ (accessed 30 September 2021). Search in Google Scholar

3 NHS England Specialised Services Clinical Reference Group for Specialised Blood Disorders. Clinical Commissioning Policy: Emicizumab prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages). 170134P. NHS England, August 2019. Available from https://www.england.nhs.uk/publication/emicizumab-as-prophylaxis-in-people-with-severe-congenital-haemophilia-a-without-factor-viii-inhibitors-all-ages/ (accessed 30 September 2021). NHS England Specialised Services Clinical Reference Group for Specialised Blood Disorders Clinical Commissioning Policy: Emicizumab prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages) 170134P. NHS England, August 2019 Available from https://www.england.nhs.uk/publication/emicizumab-as-prophylaxis-in-people-with-severe-congenital-haemophilia-a-without-factor-viii-inhibitors-all-ages/ (accessed 30 September 2021). Search in Google Scholar

4 Cancer Research UK. Myeloma incidence statistics. Available from https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence (accessed 12 April 2021). Cancer Research UK Myeloma incidence statistics Available from https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma/incidence (accessed 12 April 2021). Search in Google Scholar

5 Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 2016; 127(21): 2569–2574. doi: 10.1182/blood-2016-01-693580. MoreauP HulinC MacroM VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial Blood 2016 127 21 2569 2574 10.1182/blood-2016-01-693580 27002117 Open DOISearch in Google Scholar

6 NICE. Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma. Technology appraisal guidance [TA680] Published: 03 March 2021. Available from https://www.nice.org.uk/guidance/ta680 (accessed 30 September 2021). NICE Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma Technology appraisal guidance [TA680] Published: 03 March 2021 Available from https://www.nice.org.uk/guidance/ta680 (accessed 30 September 2021). Search in Google Scholar

7 Palumbo A, Rajkumar SV, Dimopoulos MA, et al., on behalf of the International Myeloma Working Group. Prevention of thalidomide and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22(2): 414–23. doi: 10.1038/sj.leu.2405062. PalumboA RajkumarSV DimopoulosMA on behalf of the International Myeloma Working Group Prevention of thalidomide and lenalidomide-associated thrombosis in myeloma Leukemia 2008 22 2 414 23 10.1038/sj.leu.2405062 18094721 Open DOISearch in Google Scholar

8 Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus non bortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31(26): 3279–87. doi: 10.1200/JCO.2012.48.4626 SonneveldP GoldschmidtH RosiñolL Bortezomib-based versus non bortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials J Clin Oncol 2013 31 26 3279 87 10.1200/JCO.2012.48.4626 23897961 Open DOISearch in Google Scholar

9 Bradbury C A, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood 2020; 136 (9): 1091–1104. doi: 10.1182/blood.2020005125. BradburyC A CraigZ CookG Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials Blood 2020 136 9 1091 1104 10.1182/blood.2020005125 745315332438407 Open DOISearch in Google Scholar

10 Martin K, Key N. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016; 128(2): 178–184. doi: 10.1182/blood-2015-12-635094. MartinK KeyN How I treat patients with inherited bleeding disorders who need anticoagulant therapy Blood 2016 128 2 178 184 10.1182/blood-2015-12-635094 494619927106121 Open DOISearch in Google Scholar

11 Roche Products Limited. Summary of product characteristics Hemlibra 150mg/ml solution for injection. Electronic Medicines Compendium. Last updated 04 March 2021. Available from https://www.medicines.org.uk/emc/product/9043/smpc (accessed 29 Oct 2021). Roche Products Limited Summary of product characteristics Hemlibra 150mg/ml solution for injection Electronic Medicines Compendium. Last updated 04 March 2021. Available from https://www.medicines.org.uk/emc/product/9043/smpc (accessed 29 Oct 2021). Search in Google Scholar

12 Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have haemophilia A without inhibitors. N Engl J Med 2018; 379: 811–822. doi: 10.1056/NEJMoa1803550. MahlanguJ OldenburgJ Paz-PrielI Emicizumab prophylaxis in patients who have haemophilia A without inhibitors N Engl J Med 2018 379 811 822 10.1056/NEJMoa1803550 30157389 Open DOISearch in Google Scholar

13 Linari S, Castaman G. Concomitant use of rFVIIa and emicizumab in people with haemophilia A with inhibitors: current perspectives and emerging clinical evidence. Ther Clin Risk Manag 2020; 16:461–69. doi: 10.2147/TCRM.S205310. LinariS CastamanG Concomitant use of rFVIIa and emicizumab in people with haemophilia A with inhibitors: current perspectives and emerging clinical evidence Ther Clin Risk Manag 2020 16 461 69 10.2147/TCRM.S205310 725129132547043 Open DOISearch in Google Scholar

14 Schmitt C, Adamkewicz JI, Xu J, et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with haemophilia A with factor VIII inhibitors: HAVEN 1 Study. Thromb Haemost 2021; 121(3): 351–360. doi: 10.1055/s-0040-1717114. SchmittC AdamkewiczJI XuJ Pharmacokinetics and pharmacodynamics of emicizumab in persons with haemophilia A with factor VIII inhibitors: HAVEN 1 Study Thromb Haemost 2021 121 3 351 360 10.1055/s-0040-1717114 789554133086400 Open DOISearch in Google Scholar